Second‐ or third‐generation tyrosine kinase inhibitors in first‐line treatment of chronic myeloid leukemia in general population: Is there a real benefit?

INTRODUCTION: Since 2009, multiple randomized trials have shown faster and deeper responses in CML patients treated with new‐generation TKI (NG‐TKI) compared to those treated with imatinib (IM). Are the same results observed in the general population? MATERIALS AND METHODS: Patients were identified...

Descripción completa

Detalles Bibliográficos
Autores principales: Canet, Jim, Cony‐Makhoul, Pascale, Orazio, Sébastien, Cornet, Edouard, Troussard, Xavier, Maynadié, Marc, Étienne, Gabriel, Monnereau, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Researcher
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525157/
https://www.ncbi.nlm.nih.gov/pubmed/34551198
http://dx.doi.org/10.1002/cam4.4186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525157/
https://www.ncbi.nlm.nih.gov/pubmed/34551198
http://dx.doi.org/10.1002/cam4.4186

Ejemplares similares